HK1150153A1 - Use of pramipexole to treat amyotrophic lateral sclerosis - Google Patents

Use of pramipexole to treat amyotrophic lateral sclerosis

Info

Publication number
HK1150153A1
HK1150153A1 HK11104284.4A HK11104284A HK1150153A1 HK 1150153 A1 HK1150153 A1 HK 1150153A1 HK 11104284 A HK11104284 A HK 11104284A HK 1150153 A1 HK1150153 A1 HK 1150153A1
Authority
HK
Hong Kong
Prior art keywords
pramipexole
lateral sclerosis
amyotrophic lateral
treat amyotrophic
als
Prior art date
Application number
HK11104284.4A
Other languages
English (en)
Inventor
James P Brennett
Original Assignee
Univ Virginia Patent Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Found filed Critical Univ Virginia Patent Found
Publication of HK1150153A1 publication Critical patent/HK1150153A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Artificial Filaments (AREA)
  • Noodles (AREA)
HK11104284.4A 2001-12-11 2011-04-28 Use of pramipexole to treat amyotrophic lateral sclerosis HK1150153A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33938301P 2001-12-11 2001-12-11
US34737102P 2002-01-11 2002-01-11

Publications (1)

Publication Number Publication Date
HK1150153A1 true HK1150153A1 (en) 2011-11-04

Family

ID=26991607

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11104284.4A HK1150153A1 (en) 2001-12-11 2011-04-28 Use of pramipexole to treat amyotrophic lateral sclerosis

Country Status (20)

Country Link
US (4) US7157480B2 (da)
EP (4) EP2246053B1 (da)
JP (2) JP4500543B2 (da)
KR (1) KR20040066890A (da)
CN (1) CN1617720A (da)
AT (1) ATE480235T1 (da)
AU (1) AU2002360600B2 (da)
CA (1) CA2468747C (da)
CY (1) CY1111237T1 (da)
DE (1) DE60237635D1 (da)
DK (1) DK1453505T3 (da)
ES (2) ES2351303T3 (da)
HK (1) HK1150153A1 (da)
HU (1) HUP0500001A3 (da)
IL (1) IL162408A0 (da)
MX (1) MXPA04005572A (da)
PL (1) PL374310A1 (da)
PT (1) PT1453505E (da)
RU (1) RU2004121177A (da)
WO (1) WO2003049705A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
CA2468747C (en) * 2001-12-11 2011-05-31 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
EP1940398A1 (de) * 2005-10-18 2008-07-09 Boehringer Ingelheim International GmbH Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
EP2465500A1 (en) * 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
AU2007253899A1 (en) * 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of R(+) and S(-) pramipexole and methods of using the same
AU2013209376B2 (en) * 2006-12-14 2016-05-05 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
AU2016210640B2 (en) * 2006-12-14 2018-02-22 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
JP2010513316A (ja) * 2006-12-14 2010-04-30 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソール組成物およびその使用法
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
RU2454409C2 (ru) 2007-03-14 2012-06-27 Нопп Ньюросайенсиз, Инк. Синтез хирально очищенных замещенных бензотиазолдиаминов
EP2136638A4 (en) * 2007-03-14 2010-05-12 Knopp Neurosciences Inc MODIFIED RELEASE FORMULATIONS OF (6R) -4,5,6,7-TETRAHYDRO-N6-PROPYL-2,6-BENZOTHIAZOLE DIAMINE AND METHODS OF USE THEREOF
GB0811642D0 (en) * 2008-06-25 2008-07-30 Univ Edinburgh Assay
CA2734491A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
CA2921491C (en) * 2012-08-23 2022-06-21 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
US10874669B2 (en) 2012-11-29 2020-12-29 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
WO2014085600A1 (en) * 2012-11-29 2014-06-05 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
EP3681474A1 (en) 2017-09-11 2020-07-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for nasal administration of drugs to brain and for systemic effect

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560420A (en) 1896-05-19 Steam and oil separator
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
ATE200423T1 (de) * 1995-10-26 2001-04-15 Sanofi Synthelabo Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
CA2653839A1 (en) * 1998-11-02 2000-05-11 John G. Devane Multiparticulate modified release composition
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
WO2001022820A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
CA2468747C (en) * 2001-12-11 2011-05-31 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole

Also Published As

Publication number Publication date
DE60237635D1 (de) 2010-10-21
EP2305252A1 (en) 2011-04-06
EP2246053A1 (en) 2010-11-03
EP1453505A2 (en) 2004-09-08
EP2246053B1 (en) 2013-09-18
PL374310A1 (en) 2005-10-03
US20070105918A1 (en) 2007-05-10
EP1453505B1 (en) 2010-09-08
WO2003049705A2 (en) 2003-06-19
US20050032856A1 (en) 2005-02-10
US20110301210A1 (en) 2011-12-08
MXPA04005572A (es) 2004-12-06
EP1453505A4 (en) 2007-01-10
DK1453505T3 (da) 2010-11-15
RU2004121177A (ru) 2005-03-10
HUP0500001A3 (en) 2005-11-28
US20130172394A1 (en) 2013-07-04
CN1617720A (zh) 2005-05-18
PT1453505E (pt) 2010-12-16
WO2003049705A3 (en) 2004-01-29
AU2002360600A1 (en) 2003-06-23
KR20040066890A (ko) 2004-07-27
CY1111237T1 (el) 2015-06-11
JP2005516911A (ja) 2005-06-09
US7157480B2 (en) 2007-01-02
EP2305253A1 (en) 2011-04-06
JP2010031059A (ja) 2010-02-12
ES2351303T3 (es) 2011-02-02
CA2468747A1 (en) 2003-06-19
JP4500543B2 (ja) 2010-07-14
CA2468747C (en) 2011-05-31
ES2432527T3 (es) 2013-12-04
ATE480235T1 (de) 2010-09-15
AU2002360600B2 (en) 2007-11-29
IL162408A0 (en) 2005-11-20
HUP0500001A2 (hu) 2005-04-28

Similar Documents

Publication Publication Date Title
HK1150153A1 (en) Use of pramipexole to treat amyotrophic lateral sclerosis
GB0108592D0 (en) Therapeutic agents
BG108493A (en) Beta-amino tetrahydroimidazolo(1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
IL164568A0 (en) Compounds and methods for the inhibition of the expression of vcam-1
WO2002002505A8 (en) Compounds to treat alzheimer's disease
WO2002002512A3 (en) Compounds to treat alzheimer's disease
BG108137A (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
PT1465626E (pt) Composições farmacêuticas (kit) que compreendem compostos di-hidropiridinona e um agente imunorregulador (ou antiinflamatório) e suas utilizações
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
NZ335981A (en) Ketobenzamides as calpain inhibitors
WO2002002520A8 (en) Compounds to treat alzheimer's disease
EP1068304A4 (en) TREATMENT OF PARASITAL DISEASES BY INHIBITING CYSTEIN PROTEASES OF THE PAPAIN OVERFAMILY
DE69805672D1 (de) Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
MY139368A (en) Novel cyclohexyl sulphones
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2003055440A8 (en) Compositions and methods for the treatement of immune related diseases
WO2003059387A3 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
ES2190373A1 (es) Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20221205